相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Releasable PEGylation of proteins with customized linkers
David Fipula et al.
ADVANCED DRUG DELIVERY REVIEWS (2008)
Formulation of Neulasta® (pegfilgrastim)
Deirdre Murphy Piedmonte et al.
ADVANCED DRUG DELIVERY REVIEWS (2008)
PEGylation, successful approach to drug delivery
FM Veronese et al.
DRUG DISCOVERY TODAY (2005)
Structural and biophysical characterization of the 40 kDa PEG-interferon-α2a and its individual positional isomers
C Dhalluin et al.
BIOCONJUGATE CHEMISTRY (2005)
Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals
A Natarajan et al.
BIOCONJUGATE CHEMISTRY (2005)
A new aliphatic amino prodrug system for the delivery of small molecules and proteins utilizing novel PEG derivatives
RB Greenwald et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Reversible PEGylation:: A novel technology to release native interferon α2 over a prolonged time period
T Peleg-Shulman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand
H Albrecht et al.
BIOCONJUGATE CHEMISTRY (2004)
Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation
K Yang et al.
PROTEIN ENGINEERING (2003)
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates
P Caliceti et al.
ADVANCED DRUG DELIVERY REVIEWS (2003)
Pegylation: Engineering improved biopharmaceuticals for oncology
G Molineux
PHARMACOTHERAPY (2003)
Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon α-2a (PEGASYS)
S Foser et al.
PROTEIN EXPRESSION AND PURIFICATION (2003)
Relationships between the N-glycan structures and biological activities of recombinant human erythropoietins produced using different culture conditions and purification procedures
CT Yuen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
NMR structure of two novel polyethylene glycol conjugates of the human growth hormone-releasing factor, hGRF(1-29)-NH2
G Digilio et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2003)
Controlled release of proteins from their poly(ethylene glycol) conjugates: Drug delivery systems employing 1,6-elimination
RB Greenwald et al.
BIOCONJUGATE CHEMISTRY (2003)
Effective drug delivery by PEGylated drug conjugates
RB Greenwald et al.
ADVANCED DRUG DELIVERY REVIEWS (2003)
A novel method for identifying PEGylation sites of protein using biotinylated PEG derivatives
H Lee et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2003)
Poly(ethylene glycol)-avidin bioconjugates: suitable candidates for tumor pretargeting
P Caliceti et al.
JOURNAL OF CONTROLLED RELEASE (2002)
PEGylated antibodies and antibody fragments for improved therapy: a review
AP Chapman
ADVANCED DRUG DELIVERY REVIEWS (2002)
Effects of PEG conjugation on insulin properties
KD Hinds et al.
ADVANCED DRUG DELIVERY REVIEWS (2002)
Chemistry for peptide and protein PEGylation
MJ Roberts et al.
ADVANCED DRUG DELIVERY REVIEWS (2002)
Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications
YS Wang et al.
ADVANCED DRUG DELIVERY REVIEWS (2002)
Novel effects with polyethylene glycol modified pharmaceuticals
SL Yowell et al.
CANCER TREATMENT REVIEWS (2002)
Structure, biology, and therapeutic implications of pegylated interferon alpha-2b
S Youngster et al.
CURRENT PHARMACEUTICAL DESIGN (2002)
Structural and biologic characterization of pegylated recombinant IFN-α2b
M Grace et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2001)
Rational design of a potent, long-lasting form of interferon:: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C
P Bailon et al.
BIOCONJUGATE CHEMISTRY (2001)
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
EJ Heathcote et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Peginterferon alfa-2a in patients with chronic hepatitis C
S Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C
P Glue et al.
HEPATOLOGY (2000)
Biopharmaceutical benchmarks
G Walsh
NATURE BIOTECHNOLOGY (2000)
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
H Maeda et al.
JOURNAL OF CONTROLLED RELEASE (2000)
分享论文
